Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
Maxim Group Cuts Price Target on Galena Biopharma (GALE) After Meeting with Management
-
Maxim Group Says Galena Biopharma (GALE) Fast Track is Positive and Further Validates NeuVax Potential
-
Maxim Group Bullish on Galena Biopharma (GALE) Into Interim Analysis of PRESENT Study
-
Galena Biopharma (GALE) Prices 19.8M Common Stock and Warrant Offering at $1.10/Unit
-
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants
-
Galena Biopharma (GALE) PT Cut to $4 at Maxim Group; 'Buy' Maintained
-
Notable Analyst Rating Changes 11/12: (M) (GALE) (DVN) Upgraded; (SUNE) (BSBR) (PWR) Downgraded
-
Pre-Open Stock Movers 11/12: (ANGI) (NTES) (GALE) Higher; (DSCI) (DGLY) (FRPT) Lower (more...)
-
Pre-Open Stock Movers 05/27: (EOX) (OPXA) (TIF) Higher; (KORS) (WDAY) (CHS) Lower (more...)
-
Time to Focus on Galena Biopharma (GALE) Ahead of ASCO, Maxim Group Says
-
Galena Biopharma Announces Closing of Over-Allotment Option, Increasing Total Gross Proceeds to $43.7 Million
-
Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants
-
Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants
-
Galena Biopharma (GALE) Prices 24.4M Common, Warrants Offering at $1.56/Unit
-
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants
-
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants
-
Maxim Group Maintains Bullish Thesis on Galena Biopharma (GALE) Despite SEC Investigation
-
Galena Biopharma (GALE) Prices 17.5M Offering at $2/Unit

